US healthcare giant Johnson & Johnson (J&J) has unveiled plans to invest over $55 billion in the US over the next four years. This significant investment marks a 25% increase compared to the previous four years, the company said.
Johnson & Johnson and Intra-Cellular Therapies recently entered into a definitive agreement under which Johnson & Johnson will acquire all outstanding shares of Intra-Cellular Therapies, a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders.
Johnson & Johnson has entered into a definitive agreement to acquire Ambrx, a clinical-stage biopharmaceutical company with a proprietary synthetic biology technology platform to design and develop next-generation antibody-drug conjugates (ADCs). The all-cash merger transaction for a total equity value of approximately €1.8 billion ($2.0 billion), or €1.75 billion ($1.9 billion) net of estimated cash acquired.
The US FDA approved Akeega and Talvey late last week. Phase 3 trials validated Akeega's use in the treatment of patients with BRCA-positive prostate cancer. Talvey is authorized for patients with heavily pretreated multiple myeloma.
Seeking to clear billions of dollars worth of litigation claiming that its iconic baby powder causes cancer, Johnson & Johnson has announced it is now prepared to offer a payout of $8.9 billion over 25 years to resolve all claims.
After failing yet again this week to overturn a judgment rejecting its plans to roll into a separate company more than 38,000 lawsuits claiming that its talc-based baby powder causes cancer, US healthcare giant Johnson & Johnson said it intends to file for a stay of the opinion and take its case to the Supreme Court.
Johnson & Johnson’s pharmaceuticals subsidiary Janssen is walking away from plans to launch an HIV vaccine in the immediate future after the data safety monitoring board for its latest Phase 3 trial found that the shot was no better than a placebo.
In its third fundraising round in less than two years, Hong Kong-listed globally active CDMO giant GenScript Biotech has netted a fresh $224 million capital injection for its biologics subsidiary ProBio, which was officially launched under that name in 2020.
Johnson & Johnson is finally pulling the plug on its iconic talc-based baby powder worldwide.
US health authorities are restricting the use of the Johnson & Johnson Covid vaccine somewhat belatedly, citing the rare blood clotting issues that have dogged this vaccine from the start, as well as the AstraZeneca shot.
US healthcare giant Johnson & Johnson and three major distributors, AmerisourceBergen, Cardinal Health and McKesson, have finalized a long-negotiated nationwide settlement linked to their responsibility for the opioid addiction crisis.
As wealthy countries with ample supplies of Covid-19 vaccine struggle to convince more people to get the shot, and poorer countries struggle to nail down supplies, two US vaccine makers are making negative headlines. While EU and UK approval of the Novavax vaccine was just celebrated with fanfare, that company as well as Johnson & Johnson is now said to face delivery delays.
Another US healthcare business is being split into separate parts or separated from other parts of a diverse group. First General Electric, with its health segment, went on the chopping block. This time the axe will hit the venerable Johnson & Johnson, founded in 1886 a maker of surgical dressings.
South Africa's Aspen Pharmacare aims to ramp up its Covid-19 vaccine manufacturing capacity to 1.3 billion doses per year by February 2024, from 250 to 300 million doses at present, the company has said.
As expected, Johnson & Johnson is taking its spun-off baby powder business into bankruptcy as a means of sidestepping a steadily moving avalanche of lawsuits claiming that its talc-based powder causes cancer, alternatively that it contains asbestos.
Janssen Sciences Ireland, the pharmaceutical and biotechnology arm of US healthcare giant Johnson & Johnson, has submitted a planning application for a €150 million expansion of its biomedicines facility at Ringaskiddy, County Cork.
Doses of Johnson & Johnson’s Covid-19 vaccine made at Aspen Pharmacare’s facility in South Africa and shipped to Europe to fill contractual obligations will now be sent back to Africa, the Wall Street Journal (WSJ) has reported.
Alex Gorsky, chairman and CEO of Johnson & Johnson since 2012, has announced he will step down from the healthcare giant’s top slot at the beginning of 2022 and hand over to current vice chairman of the executive committee, Joaquin Duato. With the transfer of responsibility, Gorsky will become executive chairman, and Duarto will be appointed to the board of directors.
An expert panel advising the US Centers for Disease Control (CDC) has concluded that Johnson & Johnson’s Covid-19 vaccine presents greater benefits than safety risks, especially in view of the rapid spread of the Delta variant – despite a number of cases of the nerve disease Guillain-Barré (GBS) syndrome.
A month after buying its way out of prosecution in the long-running US litigation against opioid makers for $263 million, Johnson & Johnson is now said to be weighing plans to offload liabilities from lawsuits charging that its talc-based baby powder causes ovarian cancer or mesothelioma and, alternatively, that it contains asbestos.
The prospects for Johnson & Johnson’s viral vector vaccine to play a major role in the global inoculation against Covid-19 in the developed world are looking increasingly dim. The latest blow is that the US Food and Drug Administration (FDA) is preparing to mandate a warning label that the vaccine can lead to an increased risk of Guillain–Barré syndrome, a rare but serious neurological condition.
In the aftermath of a far-reaching mix-up of Astra Zeneca’s Covid vaccine ingredients with those of Johnson & Johnson’s shot, US CDMO Emergent BioSolutions not only has lost half of its stock market value but is also facing shareholder lawsuits related to other offenses, including securities fraud.
The (almost) worst-case scenario in the mix-up of Johnson & Johnson and AstraZeneca’s Covid-19 vaccine at the Baltimore, Maryland, plant of CDMO Emergent BioSolutions apparently has occurred. After an extensive FDA probe at the site, it was determined that around 60 million J&J doses will have to be discarded, the newspaper New York Times reported.
The US Supreme Court has declined to hear Johnson & Johnson’ appeal against a $2 billion judgment in favor of 22 ovarian cancer sufferers who claimed they contracted the cancer from using the healthcare group’s talc products.
The US Food and Drug Administration will allow the restart of CDMO Emergent BioSolutions’ still shuttered Bayview plant in Baltimore, Maryland, within the next few days, the newspaper Wall Street Journal (WSJ) has reported. The paper said it understands that contamination problems at the plant have been resolved.
Problems at CDMO Emergent BioSolutions in the US state of Maryland and the resulting Food and Drug Administration shutdown of its Baltimore vaccine production facility continue to cloud the rollout of Johnson & Johnson’s Covid-19 shot. The newspaper Washington Post said the US federal government will not send any supplies of the healthcare group’s single-dose vaccine to states over the coming week, citing the weekly shipment allocation of the Centers for Disease Control (CDC).
The European Commission has confirmed rumors that it has initiated legal action against AstraZeneca for failing to meet contractual obligations for deliveries of Its Covid-19 vaccine. Health commissioner Stella Kyriakides said the action is being taken jointly with all 27 member states.
The US Centers for Disease Control and Prevention (CDC) and the Food & Drug Administration (FDA) announced on Apr. 23 that they would lift the two-week pause on administration of the Johnson & Johnson Covid-19 vaccine for all adults and require a warning label about the possibility of a rare but dangerous blood clotting disorder combined with a low level of platelets.
Johnson & Johnson will now resume the rollout of its Covid-19 vaccine in the EU, with the shot carrying a label warning that blood clots are a possible risk. The announcement came after the European Medicines Agency (EMA) said on Apr. 20 that the benefits of the vaccine exceed the risk but mandated the label.
The rollout of Johnson & Johnson’s Covid-19 vaccine could be resumed starting Apr. 23, Anthony Fauci, the top US infectious-disease expert and chief advisor to US president Joe Biden on pandemic-related issues, has told US media.
Denmark has taken what it said was a final decision to discontinue using the AstraZeneca Covid-19 vaccine in its national inoculation campaign after an unusual string of rare blood clots. A discussion has begun over what to do with the remaining supply.
US health authorities paused the rollout of Johnson & Johnson’s Covid-19 vaccine on Apr. 13 after reports of six serious blood clots occurring in nearly 7 million people vaccinated. The Food and Drug Administration (FDA) and the Centers for Disease Control (CDC) said they would release guidance following an emergency meeting on Apr. 14.
Johnson & Johnson has joined AstraZeneca in the negative spotlight, giving the latter some likely welcome relief. After studying a spate of usually rare blood-clotting issues in people receiving the Anglo-British drugmaker’s Covid-19 vaccine, the European Medicines Agency (EMA) is now looking at similar incidents with the US healthcare group’s single-dose shot.
With the backing of the US government, Johnson & Johnson has taken over “full responsibility" for manufacturing at the Bayview plant operated by its Baltimore, Maryland-based vaccine ingredients supplier, US biotech Emergent BioSolutions.
As one glitch after another at Covid vaccine suppliers upends deliveries, the German federal government is drawing up plans to build up production within its borders, federal health minister Jens Spahn said at a weekly news conference, thereby confirming remarks made by future vaccine commissioner Christoph Krupp in a pre-published newspaper interview.
